MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Cancerology is booming and immunotherapy represents the most promising approach. At the APHM we have been at the forefront of these therapeutic advances and as a radiotherapist, I’m developing new strategies combining radiotherapy and immunotherapy to reach the « abscopal effect ». MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.#clinic
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
AMU, IPC, CRCM
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.